Tempus Next
Pathways

Tempus Next for cardiology providers is a care pathway intelligence platform that empowers providers to deliver the next step in a patient’s care journey.

The platform uses AI to support clinicians in closing care gaps by identifying patients who have not received treatment consistent with applicable guidelines and delivering customized and accurate notifications directly within an established clinical workflow.

Identify and contextualize patients in their care journey

AI-enabled solutions surface deep insights from multimodal, longitudinal patient data including medical imaging, EHR data, clinician notes and time series data.

Surface precision care pathways at the point of care

Tiered and customized notifications consistent with precision medicine guidelines in the clinicians’s workflow reduce alert fatigue.

Track patients for timely follow-up to help improve outcomes

Manage current patient care effectively with Patient Tracking, search for specific patient groups using Patient Lists, and gain insights into your hospital’s patient population with our dashboards.

Increase equitable access to care

Helping clinicians with timely and accurate diagnostics, procedures, and therapies for all patients, regardless of socioeconomic status.

Figure: In this study, black patients saw a larger decrease in average time from index echo to follow-up (120 to 64 days) compared to white patients (57 to 36 days). This shows the improvement in black patients’ time to follow-up towards the average of all patients (narrowing the gap).

Horde G, Sotelo M, D’Amico A, et al. Use of an echocardiographic-based, artificial intelligence system to improve racial disparities in care of patients with valvular heart disease. European Heart Journal – Cardiovascular Imaging. 2023;24(Suppl 1):38.3.

Aorta

Tempus Next includes screening algorithms for abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) using clinician reports from abdominal ultrasounds and CTs, in addition to all other available patient data. Our system provides guidelines driven notifications and follows patients through progression from low severity to high severity.

Structural heart

Tempus Next Structural Heart capabilities include screening for appropriate care across aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonary regurgitation. Tempus Next delivers guidelines driven notifications to help providers close care gaps in these populations.

Cardiomyopathies

Within cardiomyopathies, Tempus Next screening protocols address care across non-ischemic dilated cardiomyopathy and cardiac oncologic disease. Our mission is to shorten the time to referral for consideration of advanced heart failure treatment options like left ventricular assist devices or heart transplants. We also aim to enable clinicians to track patient adherence to prescribed diagnostic studies and follow-up visits with cardiologists based on guidelines.

Electrophysiology

Tempus Next electrophysiology capabilities include screening for risk of sudden cardiac arrest (SCA), risk of left atrial appendage thrombus, and atrial fibrillation. SCA causes over 300,000 deaths annually in the United States; however, prevention is challenging due to difficulty identifying at-risk patients.¹ Less than 10% of patients who meet the AHA/ACC/HRS guidelines criteria for a primary prevention implantable cardioverter-defibrillator (ICD) receive a device, with women more likely to be undertreated.² Tempus Next continuously monitors patient data to find at-risk patients, and alerts the patient’s care team of any guidelines based follow-up or disease progression.

Guideline Directed Medical Therapies

Tempus Next screens for an array of additional conditions including congestive heart failure and ischemic heart diseases. Our program monitors length of time and patient adherence to Guideline Directed Medical Therapy, as well as key markers including ejection fraction during this period to determine the potential need for referral to a heart clinic based on guidelines. Studies have shown that patients not optimized on Guideline Directed Medical Therapy are 26% more likely to have higher annualized healthcare utilization and emergency department visits.³

1. Sudden Cardiac Arrest Foundation. January 29, 2020. Latest statistics: 1,000 people suffer sudden cardiac arrest each day in U.S.; only 10% survive [online]. Available from: https://www.sca-aware.org/sca-news/latest-statistics-1000-people-suffer-sudden-cardiac-arrest-each-day-in-us-only-10-survive [Accessed May 1, 2023]
2. Husband G.; D”amico A.; Hasnie U.; Batra N.; Cochrun S.; Gann A.; Li E.; Nguyen D.; Philip George A.; Soto M.; Rogers C.; Ahmed M.; Andrikopoulou E.; UAB Hospital, Birmingham, United States of America; University of South Alabama, Mobile, United States of America; The Johns Hopkins Hospital, Baltimore, United States of America. February 2022. European Heart Journal – Cardiovascular Imaging, Volume 23, Issue Supplement_1 [online]. Available from: https://academic.oup.com/ehjcimaging/article/23/Supplement_1/jeab289.244/6522478
3. J Comp Eff Res. October 2021. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/34225473/ [Accessed May 1, 2023]